Semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1 RA) molecule approved for the treatment of both type 2 diabetes (T2D) and obesity. has greater impact on glycated haemoglobin (HbA1c) reduction, compared to other GLP-1 RAs, first this class available in oral formulation T2D therapy, representing useful option subjects physicians less prone start an injective drug. Interestingly, ...